PMH-C PSI MEDICATIONS AND CAM COURSE EXAM
ACTUAL EXAM 2026/2027 - 100% VERIFIED QUESTIONS
& ANSWERS - PASS GUARANTEED - A+ GRADED
150 QUESTIONS
TABLE OF CONTENTS
# TOPIC
1 Demonstrate mastery of core concepts
2 C PSI Medications and CAM Course Exam Actual Exam 2026
3 2027
4 100% Verified Questions & Answers
5 Pass Guaranteed
6 A+ Graded
7 Foundations of PMH-C PSI Medications and CAM Course Exam Actual Exam 2026/2027 - 100% Verified
Questions & Answers - Pass Guaranteed - A+ Graded
8 Applied PMH-C PSI Medications and CAM Course Exam Actual Exam 2026/2027 - 100% Verified
Questions & Answers - Pass Guaranteed - A+ Graded
9 Advanced PMH-C PSI Medications and CAM Course Exam Actual Exam 2026/2027 - 100% Verified
Questions & Answers - Pass Guaranteed - A+ Graded
10 PMH-C PSI Medications and CAM Course Exam Actual Exam 2026/2027 - 100% Verified Questions &
Answers - Pass Guaranteed - A+ Graded Review
Page 1
,Q1 DEMONSTRATE MASTERY OF CORE CONCEPTS
In a patient with treatment-resistant perinatal depression who has failed two
adequate SSRI trials, which pharmacogenomic profile most strongly predicts
non-response to serotonin reuptake inhibitors and would warrant consideration of
a non-serotonergic agent?
A. CYP2D6 ultrarapid metabolizer status
B. SLC6A4 5-HTTLPR short/short (S/S) genotype CORRECT
C. HTR2A T/T polymorphism at rs6313
D. CYP2C19 poor metabolizer status
RATIONALE: The 5-HTTLPR S/S genotype is associated with reduced serotonin transporter
expression and poorer response to SSRIs, making non-serotonergic options more appropriate.
CYP2D6 ultrarapid metabolizers affect drug metabolism, not target response. HTR2A variants
influence atypical antipsychotic response, and CYP2C19 poor metabolizers primarily impact
prodrug activation, not intrinsic SSRI efficacy.
Q2 DEMONSTRATE MASTERY OF CORE CONCEPTS
Which of the following best describes the pharmacodynamic interaction that
underlies the serotonin syndrome risk when combining linezolid with an SSRI in
the perinatal period?
A. Irreversible inhibition of monoamine oxidase-A leading to reduced serotonin metabolism
CORRECT
B. Competitive antagonism at the serotonin 5-HT2A receptor
C. Inhibition of CYP2D6 causing elevated SSRI plasma concentrations
D. Enhanced serotonin reuptake blockade at the synaptic cleft
RATIONALE: Linezolid is a reversible, non-selective MAO inhibitor, but its primary
pharmacodynamic effect is MAO-A inhibition, which prevents serotonin breakdown, leading to
excess synaptic serotonin when combined with an SSRI. It is not a receptor antagonist, CYP
inhibitor, or reuptake enhancer. This interaction is a classic cause of serotonin syndrome.
Page 2
,Q3 DEMONSTRATE MASTERY OF CORE CONCEPTS
A breastfeeding patient with postpartum depression is prescribed sertraline.
Which of the following pharmacokinetic properties makes sertraline a preferred
agent during lactation, and what is the clinical implication for the infant?
A. High protein binding and low milk-to-plasma ratio; infant exposure is typically subtherapeutic
CORRECT
B. Long half-life and active metabolite; infant exposure accumulates over time
C. Low oral bioavailability in infants; no measurable plasma levels
D. High lipophilicity; extensive transfer into breast milk
RATIONALE: Sertraline has high protein binding (98%) and a low milk-to-plasma ratio, resulting
in low infant plasma concentrations that are usually below the limit of quantification. This
minimizes the risk of adverse effects in the breastfed infant. Long half-life and active metabolites
would increase exposure, and low oral bioavailability is not a characteristic of sertraline.
Q4 DEMONSTRATE MASTERY OF CORE CONCEPTS
According to current expert consensus, which of the following is the most
appropriate first-line pharmacological strategy for a patient with severe
postpartum psychosis who is refusing oral medications?
A. Initiate a long-acting injectable antipsychotic after a trial of oral risperidone
B. Use a combination of an antipsychotic and a benzodiazepine, with rapid dose titration
C. Administer a short-acting intramuscular antipsychotic, such as haloperidol, with close
monitoring CORRECT
D. Delay pharmacotherapy and rely on electroconvulsive therapy as the sole treatment
RATIONALE: In acute postpartum psychosis, when oral medications are refused, a short-acting
intramuscular antipsychotic (e.g., haloperidol) is recommended for rapid symptom control and
safety. Long-acting injectables are reserved for maintenance non-adherence, not acute refusal.
Combining with benzodiazepines may be used but is not the first-line sole strategy. ECT is highly
effective but not the sole treatment when medication refusal occurs.
Page 3
, Q5 DEMONSTRATE MASTERY OF CORE CONCEPTS
A patient with premenstrual dysphoric disorder (PMDD) is considering treatment
with a continuous combined oral contraceptive. Which of the following
mechanisms best explains the efficacy of this approach, and what is the
recommended first-line regimen?
A. Suppression of ovulation and stabilization of gonadal steroid fluctuations; use a monophasic
pill with 20-30 mcg ethinyl estradiol continuously CORRECT
B. Augmentation of progesterone to counteract estrogen dominance; use a biphasic pill with a
shortened hormone-free interval
C. Selective serotonin reuptake inhibition via the pill's active metabolite; use a pill containing
drospirenone and ethinyl estradiol in a 24/4 regimen
D. Induction of anovulation and endometrial atrophy; use a pill with 50 mcg ethinyl estradiol and
a 7-day placebo week
RATIONALE: Continuous combined oral contraceptives suppress ovulation and stabilize the
fluctuations of estrogen and progesterone that trigger PMDD symptoms. A monophasic pill with
20-30 mcg ethinyl estradiol taken continuously (no hormone-free interval) is recommended.
Biphasic pills and those with a 7-day placebo week do not provide stable hormone levels.
Drospirenone-containing pills are effective but the mechanism is not SSRI-like.
Q6 DEMONSTRATE MASTERY OF CORE CONCEPTS
A patient with postpartum depression is treated with brexanolone. Which of the
following statements accurately describes the mechanism of action and a key
clinical consideration for this therapy?
A. Positive allosteric modulation of GABA-A receptors; requires a 60-hour continuous
intravenous infusion in a certified healthcare facility CORRECT
B. Selective serotonin reuptake inhibition; administered as a daily oral tablet
C. Antagonism at the NMDA receptor; given as a single intramuscular injection
D. Inhibition of corticotropin-releasing factor; requires a 2-week oral taper
RATIONALE: Brexanolone is a neuroactive steroid that acts as a positive allosteric modulator at
GABA-A receptors, and it is administered as a 60-hour continuous IV infusion under Risk
Evaluation and Mitigation Strategy (REMS) in a certified facility. It is not an SSRI, NMDA
antagonist, or CRF inhibitor.
Page 4
ACTUAL EXAM 2026/2027 - 100% VERIFIED QUESTIONS
& ANSWERS - PASS GUARANTEED - A+ GRADED
150 QUESTIONS
TABLE OF CONTENTS
# TOPIC
1 Demonstrate mastery of core concepts
2 C PSI Medications and CAM Course Exam Actual Exam 2026
3 2027
4 100% Verified Questions & Answers
5 Pass Guaranteed
6 A+ Graded
7 Foundations of PMH-C PSI Medications and CAM Course Exam Actual Exam 2026/2027 - 100% Verified
Questions & Answers - Pass Guaranteed - A+ Graded
8 Applied PMH-C PSI Medications and CAM Course Exam Actual Exam 2026/2027 - 100% Verified
Questions & Answers - Pass Guaranteed - A+ Graded
9 Advanced PMH-C PSI Medications and CAM Course Exam Actual Exam 2026/2027 - 100% Verified
Questions & Answers - Pass Guaranteed - A+ Graded
10 PMH-C PSI Medications and CAM Course Exam Actual Exam 2026/2027 - 100% Verified Questions &
Answers - Pass Guaranteed - A+ Graded Review
Page 1
,Q1 DEMONSTRATE MASTERY OF CORE CONCEPTS
In a patient with treatment-resistant perinatal depression who has failed two
adequate SSRI trials, which pharmacogenomic profile most strongly predicts
non-response to serotonin reuptake inhibitors and would warrant consideration of
a non-serotonergic agent?
A. CYP2D6 ultrarapid metabolizer status
B. SLC6A4 5-HTTLPR short/short (S/S) genotype CORRECT
C. HTR2A T/T polymorphism at rs6313
D. CYP2C19 poor metabolizer status
RATIONALE: The 5-HTTLPR S/S genotype is associated with reduced serotonin transporter
expression and poorer response to SSRIs, making non-serotonergic options more appropriate.
CYP2D6 ultrarapid metabolizers affect drug metabolism, not target response. HTR2A variants
influence atypical antipsychotic response, and CYP2C19 poor metabolizers primarily impact
prodrug activation, not intrinsic SSRI efficacy.
Q2 DEMONSTRATE MASTERY OF CORE CONCEPTS
Which of the following best describes the pharmacodynamic interaction that
underlies the serotonin syndrome risk when combining linezolid with an SSRI in
the perinatal period?
A. Irreversible inhibition of monoamine oxidase-A leading to reduced serotonin metabolism
CORRECT
B. Competitive antagonism at the serotonin 5-HT2A receptor
C. Inhibition of CYP2D6 causing elevated SSRI plasma concentrations
D. Enhanced serotonin reuptake blockade at the synaptic cleft
RATIONALE: Linezolid is a reversible, non-selective MAO inhibitor, but its primary
pharmacodynamic effect is MAO-A inhibition, which prevents serotonin breakdown, leading to
excess synaptic serotonin when combined with an SSRI. It is not a receptor antagonist, CYP
inhibitor, or reuptake enhancer. This interaction is a classic cause of serotonin syndrome.
Page 2
,Q3 DEMONSTRATE MASTERY OF CORE CONCEPTS
A breastfeeding patient with postpartum depression is prescribed sertraline.
Which of the following pharmacokinetic properties makes sertraline a preferred
agent during lactation, and what is the clinical implication for the infant?
A. High protein binding and low milk-to-plasma ratio; infant exposure is typically subtherapeutic
CORRECT
B. Long half-life and active metabolite; infant exposure accumulates over time
C. Low oral bioavailability in infants; no measurable plasma levels
D. High lipophilicity; extensive transfer into breast milk
RATIONALE: Sertraline has high protein binding (98%) and a low milk-to-plasma ratio, resulting
in low infant plasma concentrations that are usually below the limit of quantification. This
minimizes the risk of adverse effects in the breastfed infant. Long half-life and active metabolites
would increase exposure, and low oral bioavailability is not a characteristic of sertraline.
Q4 DEMONSTRATE MASTERY OF CORE CONCEPTS
According to current expert consensus, which of the following is the most
appropriate first-line pharmacological strategy for a patient with severe
postpartum psychosis who is refusing oral medications?
A. Initiate a long-acting injectable antipsychotic after a trial of oral risperidone
B. Use a combination of an antipsychotic and a benzodiazepine, with rapid dose titration
C. Administer a short-acting intramuscular antipsychotic, such as haloperidol, with close
monitoring CORRECT
D. Delay pharmacotherapy and rely on electroconvulsive therapy as the sole treatment
RATIONALE: In acute postpartum psychosis, when oral medications are refused, a short-acting
intramuscular antipsychotic (e.g., haloperidol) is recommended for rapid symptom control and
safety. Long-acting injectables are reserved for maintenance non-adherence, not acute refusal.
Combining with benzodiazepines may be used but is not the first-line sole strategy. ECT is highly
effective but not the sole treatment when medication refusal occurs.
Page 3
, Q5 DEMONSTRATE MASTERY OF CORE CONCEPTS
A patient with premenstrual dysphoric disorder (PMDD) is considering treatment
with a continuous combined oral contraceptive. Which of the following
mechanisms best explains the efficacy of this approach, and what is the
recommended first-line regimen?
A. Suppression of ovulation and stabilization of gonadal steroid fluctuations; use a monophasic
pill with 20-30 mcg ethinyl estradiol continuously CORRECT
B. Augmentation of progesterone to counteract estrogen dominance; use a biphasic pill with a
shortened hormone-free interval
C. Selective serotonin reuptake inhibition via the pill's active metabolite; use a pill containing
drospirenone and ethinyl estradiol in a 24/4 regimen
D. Induction of anovulation and endometrial atrophy; use a pill with 50 mcg ethinyl estradiol and
a 7-day placebo week
RATIONALE: Continuous combined oral contraceptives suppress ovulation and stabilize the
fluctuations of estrogen and progesterone that trigger PMDD symptoms. A monophasic pill with
20-30 mcg ethinyl estradiol taken continuously (no hormone-free interval) is recommended.
Biphasic pills and those with a 7-day placebo week do not provide stable hormone levels.
Drospirenone-containing pills are effective but the mechanism is not SSRI-like.
Q6 DEMONSTRATE MASTERY OF CORE CONCEPTS
A patient with postpartum depression is treated with brexanolone. Which of the
following statements accurately describes the mechanism of action and a key
clinical consideration for this therapy?
A. Positive allosteric modulation of GABA-A receptors; requires a 60-hour continuous
intravenous infusion in a certified healthcare facility CORRECT
B. Selective serotonin reuptake inhibition; administered as a daily oral tablet
C. Antagonism at the NMDA receptor; given as a single intramuscular injection
D. Inhibition of corticotropin-releasing factor; requires a 2-week oral taper
RATIONALE: Brexanolone is a neuroactive steroid that acts as a positive allosteric modulator at
GABA-A receptors, and it is administered as a 60-hour continuous IV infusion under Risk
Evaluation and Mitigation Strategy (REMS) in a certified facility. It is not an SSRI, NMDA
antagonist, or CRF inhibitor.
Page 4
